Open Access<p>Tumor Response to Irinotecan is Associated with IL-10 Expression Level in Metastatic Colorectal Cancer-Results from mCRC Biomarker Study</p>
Author(s) -
Jinjia Chang,
Wen Zhang,
Guang-Yi Lin,
Duo Tong,
Dan Zhu,
Jing Zhao,
Qihe Yu,
Dan Huang,
Wenhua Li
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s275636
Subject(s) - irinotecan , medicine , oxaliplatin , colorectal cancer , regimen , oncology , hazard ratio , proportional hazards model , chemotherapy , biomarker , folfiri , cancer , gastroenterology , confidence interval , biochemistry , chemistry
Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related death. Resistance to chemotherapy is the main reason for the failure of the treatment of mCRC. IL-10 has been reported to decrease after surgery and increase after mCRC reoccurrence. The role of IL-10 in chemotherapy drug resistance of mCRC is not well elucidated.